Home › Search
Search
439 results for "lecanemab".
Research summaries 393
Showing the best 200 of 393, 11–20, page 2 of 20. Filter these by subject, year and score in the research library →
-
Re-evaluation of the efficacy and safety of anti-Aβ monoclonal antibodies (lecanemab/donanemab) in the treatment of early Alzheimer's diseaseResearch summary
Research summaries · alzhub.org/study/re-evaluation-of-the-efficacy-and-safety-of-anti-a-monoclonal-40308765
… monoclonal antibodies (Lecanemab/Donanemab) in the treatment of early Alzheimer's disease (AD) and to provide evidence for rational clinical use. Methods We searched databases including PubMed, Embase, Cochrane, Web of Science, …
-
Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trialsResearch summary
Research summaries · alzhub.org/study/safety-and-efficacy-of-lecanemab-for-alzheimer-s-disease-a-systematic-37213538
… effectiveness and safety of lecanemab on subjects with Alzheimer's disease (AD). Methods We screened the literature published before February 2023 in PubMed, Embase, Web of Science, and Cochrane that were searched for randomized …
-
Updated safety results from phase 3 lecanemab study in early Alzheimer's diseaseResearch summary
Research summaries · alzhub.org/study/updated-safety-results-from-phase-3-lecanemab-study-in-early-38730496
… at least one dose of lecanemab (Core + OLE) were included. This report gives updated safety results from a phase 3 lecanemab study in early Alzheimer's disease, covering 1795 participants in the core study and 1612 who received …
-
Research summaries · alzhub.org/study/comparative-efficacy-tolerability-and-acceptability-of-donanemab-38253184
… efficacy of donanemab and lecanemab was significantly higher than placebo. Compared to placebo, donanemab and lecanemab were significantly less acceptable and tolerable. Aducanumab was also less well tolerated compared to …
-
Efficacy and safety of aducanumab, lecanemab, and donanemab in Alzheimer's disease: A meta-analysis of randomized controlled trialsResearch summary
Research summaries · alzhub.org/study/efficacy-and-safety-of-aducanumab-lecanemab-and-donanemab-in-42803728
… safety of aducanumab, lecanemab, and donanemab in randomized placebo-controlled trials.MethodsPubMed, Cochrane, and ClinicalTrials.gov were searched through February 2026 for randomized placebo-controlled trials evaluating …
-
Research summaries · alzhub.org/study/comparative-efficacy-tolerability-and-acceptability-of-aducanumab-40386876
… effective than aducanumab, lecanemab, and donanemab. Furthermore, rTMS was not significantly inferior to placebo/sham stimulation in tolerability and acceptability, whereas aducanumab, lecanemab, and donanemab were significantly …
-
Lecanemab: Appropriate Use RecommendationsResearch summary
Research summaries · alzhub.org/study/lecanemab-appropriate-use-recommendations-37357276
Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild AD dementia) with confirmed brain amyloid …
-
Research summaries · alzhub.org/study/the-efficacy-and-safety-of-lecanemab-10-mg-kg-biweekly-compared-to-a-38565747
… effective interventions. Lecanemab, a monoclonal antibody targeting amyloid-beta plaques, shows promise in slowing Alzheimer's progression. Positive clinical trial results have instilled hope in patients, prompting ongoing …
-
Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer diseaseResearch summary
Research summaries · alzhub.org/study/lecanemab-ban2401-an-anti-beta-amyloid-monoclonal-antibody-for-the-36749830
… more specific Aβ types. Lecanemab Eisai has a high affinity for large and soluble Aβ protofibrils. This review describes lecanemab, an anti-beta-amyloid monoclonal antibody with high affinity for large soluble Aβ protofibrils, …
-
Research summaries · alzhub.org/study/a-randomized-double-blind-phase-2b-proof-of-concept-clinical-trial-in-33865446
Background Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils, and insoluble fibrils. BAN2401-G000-201, a randomized …
How this search works
There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.
One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.
31503 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-13. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.